Core-- Pharmacology

Pesce, Amadeo J.

Abstract

The University of Cincinnati Division of Toxicology is uniquely qualified to serve as an ACTG Pharmacology Core Laboratory. Through the Division's research and development programs, its commitment in the battle against HIV disease has been documented through numerous publications and abstracts, and by the initiation of ACTG 161, a pharmacokinetic study of total phosphorylated zidovudine in HIV-infected patients. The Division of Toxicology can offer a full range of State- of-the-Art equipment and experience, and currently represents the leading edge in the development of assays for active intracellular metabolites of nucleoside analogs in patients, specifically zidovudine. Currently, the University of Cincinnati Division of Toxicology is the only laboratory capable of performing assays for ACTG 161, and any similar future studies. Because the Division is hospital based, procedures and facilities for sample receipt, handling, storage, and billing are already in place. Furthermore, as a clinical laboratory, adherence to strict regulated standards of quality assurance and control are required. The Division of Toxicology has a strong history of cooperation with the University of Cincinnati ACTU, and hopes to continue the same level of cooperation in the future.

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Institute of Allergy and Infectious Diseases (NIAID)
• Type: Research Project--Cooperative Agreements (U01)
• Project #: 5U01AI025897-08
• Application #: 3727041
• Support Year: 8
• Fiscal Year: 1995

Institution

• Name: University of Cincinnati
• City: Cincinnati
• State: OH
• Country: United States
• Zip Code: 45221

Publications

Grady, Benjamin J; Torstenson, Eric S; McLaren, Paul J et al. (2011) Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants. Pac Symp Biocomput :253-64

Sherman, Kenneth E; Rouster, Susan D; Stanford, Sandra et al. (2010) Hepatitis C virus (HCV) quasispecies complexity and selection in HCV/HIV-coinfected subjects treated with interferon-based regimens. J Infect Dis 201:712-9

Bhattacharya, Debika; Umbleja, T; Carrat, F et al. (2010) Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis. J Acquir Immune Defic Syndr 55:170-5

Zhao, Yu; Navia, Bradford A; Marra, Christina M et al. (2010) Memantine for AIDS dementia complex: open-label report of ACTG 301. HIV Clin Trials 11:59-67

Fichtenbaum, Carl J; Yeh, Tzu-Min; Evans, Scott R et al. (2010) Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. J Clin Lipidol 4:279-87

Winham, Stacey J; Slater, Andrew J; Motsinger-Reif, Alison A (2010) A comparison of internal validation techniques for multifactor dimensionality reduction. BMC Bioinformatics 11:394

Butt, Adeel A; Tsevat, Joel; Leonard, Anthony C et al. (2009) Effect of race and HIV co-infection upon treatment prescription for hepatitis C virus. Int J Infect Dis 13:449-55

Tsevat, Joel; Leonard, Anthony C; Szaflarski, Magdalena et al. (2009) Change in quality of life after being diagnosed with HIV: a multicenter longitudinal study. AIDS Patient Care STDS 23:931-7

Skowron, Gail; Spritzler, John G; Weidler, Jodi et al. (2009) Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects. J Acquir Immune Defic Syndr 50:250-8

McComsey, Grace A; Kang, Minhee; Ross, Allison C et al. (2008) Increased mtDNA levels without change in mitochondrial enzymes in peripheral blood mononuclear cells of infants born to HIV-infected mothers on antiretroviral therapy. HIV Clin Trials 9:126-36